Sleep-Deprived Adults at Higher Risk for Dementia

May 15, 2021 0 Comments

Adults who sleep 6 hours or less increase their dementia risk by 30% according to a recent study published in Nature Communications.

Existing studies that assess sleep duration over more than 10 years primarily involve adults age 65 and older. The researchers wanted to assess the relationship between sleep and dementia beginning at age 50.

The researchers used data from the Whitehall II cohort study that includes British civil servants and spans 30 years. They assessed the association between sleep duration and dementia at age 50, 60, and 70. They also looked at the relationship between mental disorders in midlife, sleep duration, and dementia.

The study included data from 10,308 individuals — 7,959 had data on sleep duration at age 50.


Continue Reading

Among the participants with sleep data, 521 developed dementia over a mean follow-up period of 24.6 (SD = 7.0) years. The follow-up was 25.7 (SD = … Read the rest

Zynrelef Approved to Treat Postoperative Pain for Up to 72 Hours

May 14, 2021 0 Comments

The Food and Drug Administration (FDA) has approved Zynrelef (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours in adults after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.

Zynrelef is a dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine, an amide local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID). The needle-free product is intended for single-dose administration only.

The approval was based on data from multiple double-blind, placebo- and active-controlled phase 3 (ClinicalTrials.gov: NCT03295721, NCT03237481) and phase 2 (ClinicalTrials.gov: NCT03015532) studies involving over 1000 patients.

Among patients undergoing unilateral simple bunionectomy (N=412), treatment with Zynrelef was associated with a significant reduction in pain intensity compared with either bupivacaine HCl or saline placebo for up to 72 hours. Additionally, a significant proportion of patients in the Zynrelef arm did not receive opioid … Read the rest

Vaginal pH Regulator Gets Fast Track Status for Gonorrhea Prevention

May 13, 2021 0 Comments

The Food and Drug Administration (FDA) has granted Fast Track designation to EVO100 for the prevention of urogenital gonorrhea in women. 

EVO100 is pH-modulating vaginal gel designed to reduce certain vaginal infections by balancing vaginal pH, thereby maintaining healthy vaginal flora. The designation is supported by data from the double-blind, placebo-controlled phase 2b/3 AMPREVENCE trial (ClinicalTrials.gov: NCT03107377), which assessed the efficacy and safety of EVO100 in reducing the risk of gonorrhea and chlamydia infections in 860 women.

Patients were randomly assigned 1:1 to receive EVO100 (n=426) or placebo (n=434) intravaginally at least 1 hour prior to vaginal intercourse. Results showed that EVO100 met the primary and secondary endpoints with statistically significant reductions in the risk of chlamydia and gonorrhea, respectively.

The chlamydia infection rate for the EVO100 arm was 4.8% (n=14/289) compared with 9.7% (n=28/290) for placebo (P =.0256), indicating a relative risk reduction of 50%. The gonorrhea infection … Read the rest

Expert Q&A: MAPS and Psychedelic-Assisted Psychotherapy

May 12, 2021 0 Comments

After decades of limited research and legal roadblocks to medical and recreational use, psychedelic drugs are rapidly remerging as treatments of interest in psychiatry. Cannabis for medical use is widely available across the United States, and in the 2020 elections, a number of states relaxed drug laws, with Oregon allowing psychedelic treatments at medical centers.1

These legal changes, particularly regarding nonmedical or recreational use, will have many physicians worried about the development of substance use disorders in broad swathes of the population. However, relaxed regulations may offer an opportunity to learn more about how the diverse range of psychedelic drugs can be applied as treatments in psychiatric settings.2-4

The first part of this series of articles (Psychedelic Drugs: Lessons From Ketamine and Psilocybin) explored a couple of very different psychedelic treatments for psychiatric disorders, namely esketamine and psilocybin-based treatments for major depressive disorder (MDD).5 Whereas the development … Read the rest

Health Risks From Plastic Water Pipes

May 11, 2021 0 Comments

Everyone knows that neither group is experiencing optimum situations for longevity. Along with Dr. Marie Nyswander and Dr. Kreek, Dole pioneered methadone therapy for heroin addicts.

jaguar health news 2021

The International Health Briefing Book is a resource for effectively-informed resolution-making on issues involving U.S. engagement in global well being. In 1986, the WHO, within the Ottawa Constitution for Health Promotion, said that well being is “a resource for on a regular basis life, not the objective of dwelling. Well being is a constructive idea emphasizing social and private assets, in addition to bodily capacities.” Classification systems such because the WHO Household of Worldwide Classifications (WHO-FIC), which consists canadian pharmacy of the Worldwide Classification of Functioning, Disability, and Well being (ICF) and the Worldwide Classification of Diseases (ICD) also outline health. The report reveals health care prices are additionally a leading contributor to health inequities. For instance, 6{d88ec4a771b38d36e747acb18ed3240a91adf6c3faa273fad2adf67e1f235525} of adults … Read the rest

Tezepelumab BLA Submitted for Severe Asthma

May 11, 2021 0 Comments

The Biologics License Application (BLA) for tezepelumab has been submitted to the Food and Drug Administration (FDA) for patients with severe asthma.

Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin, an epithelial cytokine involved in the initiation and persistence of airway inflammation. 

The BLA submission is supported by data from the PATHFINDER clinical program, which included the double-blind, placebo-controlled phase 3 NAVIGATOR trial (ClinicalTrials.gov: NCT03347279) that assessed the efficacy and safety of tezepelumab in 1061 patients 12 to 80 years of age with severe, uncontrolled asthma who were receiving medium- or high-dose inhaled corticosteroid plus at least 1 additional controller medication with or without oral corticosteroid. The study included patients with both high and low blood eosinophil counts.

Patients were randomly assigned 1:1 to receive tezepelumab or placebo administered by subcutaneous injection, in addition to standard of care. The primary end point of … Read the rest

Electronic Nicotine Delivery System May Reduce Toxicant Exposure, Cigarette Consumption

May 10, 2021 0 Comments

People using electronic nicotine delivery systems (ENDS) with cigarette-like nicotine delivery may reduce their exposure to a tobacco-specific carcinogen metabolite, even with concurrent smoking, according to study results published in The Lancet Respiratory Medicine.

Investigators conducted a 4-arm, parallel-group, randomized controlled study (ClinicalTrials.gov Identifier: NCT02342795) to determine how much ENDS or nonnicotine cigarette substitutes influence toxicant exposure related to tobacco and cigarette consumption in individuals who were interested in reducing their smoking frequency.

Adults aged 21 to 65 years who smoked more than 9 cigarettes a day for at least the past year, who wanted to reduce their smoking frequency, but not quit, were invited to be randomly assigned to receive either a cartomizer-based, pen-style ENDS with 0 mg/mL, 8 mg/mL, or 36 mg/mL liquid nicotine or a nonelectronic cigarette-shaped plastic tube that contained no nicotine or aerosol (cigarette substitute; unmasked) for 24 weeks.

The primary outcome measured the concentration … Read the rest

Strategies for Managing Uncertainty in Patient Care

May 9, 2021 0 Comments

One of the central themes of physicians’ professional lives this past year has been the lack of certainty when addressing COVID-19. From a public health perspective, the knowledge base over the importance of face masking has changed and evolved while the risks and benefits of various formulations of COVID vaccines have shifted. From a patient care perspective, what constitutes an effective and safe therapeutic against SARS-CoV-2 has been less a certainty and more of an evolving science. Although these gaps in knowledge are expected in medicine, they feel more significant now and are probably likely to increase. The public has confronted the widespread uncertainty as well, and has had to struggle to learn how to adapt to the evolving knowledge base. 

Uncertainty, which is the conscious awareness of not fully knowing, is central to the experience of caring for patients.1 Diagnostic, prognostic and treatment processes in patient care are … Read the rest

Impact of the COVID-19 Pandemic on Adolescent Mental Health

May 7, 2021 0 Comments

Even before the COVID-19 pandemic began, concerning mental health trends and major treatment gaps were noted among adolescents in the United States. According to data from the National Survey on Drug Use and Health, an estimated 13.3% of US adolescents aged 12-17 experienced at least 1 episode of major depressive disorder in 2017, yet 60.1% of these individuals did not receive treatment for their illness.1

In addition, survey results from the Centers for Disease Control and Prevention demonstrated increasing rates of US high school students experiencing persistent sadness or hopelessness (from approximately 26% in 2009 to 37% in 2019), serious contemplation of suicide (from 14% to 19%), suicide planning (from 11% to 16%), and suicide attempts (from 6% to 9%). The highest risk levels were observed for White, female, and sexual minority students compared with non-White, male, and heterosexual students.2

Early findings indicate that these issues are being … Read the rest

New Guidance: American College of Physicians Discusses Antibody Response in COVID-19 Immunity

May 6, 2021 0 Comments

Because of the novelty of the coronavirus that causes COVID-19, there is not enough evidence to determine whether antibodies produced after exposure are protective against reinfection. As such, the American College of Physicians (ACP) published rapid, evidence-based living practice points in the Annals of Internal Medicine discussing the role of antibodies in, tests for diagnosing, and tests for estimating the prevalence of COVID-19.

Practice Point 1: Antibody Tests for COVID-19 Diagnosis

The ACP does not recommend using SARS-CoV-2 antibody tests to diagnose COVID-19. This recommendation is based on the limited evidence that suggests not all patients with COVID-19 develop antibodies early in the course of their infection, as the presence and levels of antibodies can vary across patients and be dictated by certain disease characteristics.

The guideline panel adds that clinicians and patients should be mindful that some SARS-CoV-2 antibody tests may provide false-positive results, which are caused by cross-reactivity … Read the rest